



Online article and related content
current as of July 6, 2009.

Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein

David J. A. Jenkins; Cyril W. C. Kendall; Augustine Marchie; et al.

JAMA. 2003;290(4):502-510 (doi:10.1001/jama.290.4.502)

<http://jama.ama-assn.org/cgi/content/full/290/4/502>

Correction	Contact me if this article is corrected.
Citations	This article has been cited 152 times. Contact me when this article is cited.
Topic collections	Nutritional and Metabolic Disorders; Lipids and Lipid Disorders Contact me when new articles are published in these topic areas.
Related Articles published in the same issue	Diet First, Then Medication for Hypercholesterolemia James W. Anderson. <i>JAMA</i>. 2003;290(4):531.
Related Letters	Ethical Aspects of Recommending Lifestyle Interventions to Patients Robert M. Veatch. <i>JAMA</i>. 2003;290(20):2660. Isoflavones and Postmenopausal Women Cesare R. Sirtori. <i>JAMA</i>. 2004;292(19):2336.

Subscribe
<http://jama.com/subscribe>

Permissions
permissions@ama-assn.org
<http://pubs.ama-assn.org/misc/permissions.dtl>

Email Alerts
<http://jamaarchives.com/alerts>

Reprints/E-prints
reprints@ama-assn.org

Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein

David J. A. Jenkins, MD

Cyril W. C. Kendall, PhD

Augustine Marchie, BSc

Dorothea A. Faulkner, PhD

Julia M. W. Wong, RD

Russell de Souza, RD

Azadeh Emam, BSc

Tina L. Parker, RD

Edward Vidgen, BSc

Karen G. Lapsley, DSc

Elke A. Trautwein, PhD

Robert G. Josse, MB,BS

Lawrence A. Leiter, MD

Philip W. Connelly, PhD

MOST DIETARY MANIPULATIONS result in modest cholesterol reductions of 4% to 13%,¹⁻¹⁰ and diet has been considered by some as a relatively ineffective therapy.¹¹ In contrast, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) repeatedly have been shown to reduce mean serum low-density lipoprotein cholesterol (LDL-C) concentrations by 28% to 35% in long-term trials,¹²⁻¹⁴ with corresponding reductions in cardiovascular death of 23% to 32% in both primary and secondary prevention trials.^{13,14} Recently, to boost effectiveness of diet for primary prevention of cardiovascular disease, the Adult Treatment Panel (ATP III)

For editorial comment see p 531.

Context To enhance the effectiveness of diet in lowering cholesterol, recommendations of the Adult Treatment Panel III of the National Cholesterol Education Program emphasize diets low in saturated fat together with plant sterols and viscous fibers, and the American Heart Association supports the use of soy protein and nuts.

Objective To determine whether a diet containing all of these recommended food components leads to cholesterol reduction comparable with that of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).

Design Randomized controlled trial conducted between October and December 2002.

Setting and Participants Forty-six healthy, hyperlipidemic adults (25 men and 21 postmenopausal women) with a mean (SE) age of 59 (1) years and body mass index of 27.6 (0.5), recruited from a Canadian hospital-affiliated nutrition research center and the community.

Interventions Participants were randomly assigned to undergo 1 of 3 interventions on an outpatient basis for 1 month: a diet very low in saturated fat, based on milled whole-wheat cereals and low-fat dairy foods (n=16; control); the same diet plus lovastatin, 20 mg/d (n=14); or a diet high in plant sterols (1.0 g/1000 kcal), soy protein (21.4 g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and almonds (14 g/1000 kcal) (n=16; dietary portfolio).

Main Outcome Measures Lipid and C-reactive protein levels, obtained from fasting blood samples; blood pressure; and body weight; measured at weeks 0, 2, and 4 and compared among the 3 treatment groups.

Results The control, statin, and dietary portfolio groups had mean (SE) decreases in low-density lipoprotein cholesterol of 8.0% (2.1%) ($P=.002$), 30.9% (3.6%) ($P<.001$), and 28.6% (3.2%) ($P<.001$), respectively. Respective reductions in C-reactive protein were 10.0% (8.6%) ($P=.27$), 33.3% (8.3%) ($P=.002$), and 28.2% (10.8%) ($P=.02$). The significant reductions in the statin and dietary portfolio groups were all significantly different from changes in the control group. There were no significant differences in efficacy between the statin and dietary portfolio treatments.

Conclusion In this study, diversifying cholesterol-lowering components in the same dietary portfolio increased the effectiveness of diet as a treatment of hypercholesterolemia.

JAMA. 2003;290:502-510

www.jama.com

of the National Cholesterol Education Program has recommended addition of plant sterols (2 g/d) and viscous fibers (10-25 g/d) to the diet.¹⁵ The American Heart Association has also drawn atten-

Author Affiliations and Financial Disclosures are listed at the end of this article.

Corresponding Author and Reprints: David J. A. Jenkins, MD, Clinical Nutrition and Risk Factor Modification Center, St Michael's Hospital, 61 Queen St E, Toronto, Ontario, Canada M5C 2T2 (e-mail: cyril.kendall@utoronto.ca).


tion to the possible benefits of soy proteins and the potential value of nuts.¹⁶ In turn, the US Food and Drug Administration now permits health claims for coronary heart disease (CHD) risk reduction, based on cholesterol lowering, for foods delivering adequate amounts of plant sterols,¹⁷ viscous fibers (oat β -glucan and psyllium),^{18,19} and soy protein,²⁰ and a health claim for nuts is being considered. Despite the large potential for cholesterol reduction, this dietary combination has never been compared directly with a statin. To assess the effectiveness of this dietary portfolio approach, we therefore studied a group of hyperlipidemic adults who were randomized to 1 of 3 treatments: the combination dietary portfolio, a diet lacking the additional active dietary ingredients but with a similar very low-saturated-fat content (control), or the same low-saturated-fat diet with addition of a statin.

METHODS

Participants

Fifty-five participants were recruited from hyperlipidemic patients attending the Clinical Nutrition and Risk Factor Modification Center at St Michael's Hospital, Toronto, Ontario, and from newspaper advertisements. Postmenopausal women were recruited because of the increase in LDL-C and CHD risk in women in this age group and to avoid possible fluctuations in blood lipids related to the menstrual cycle. All participants were reluctant to take statins and wished to determine the relative effectiveness of diet. Four participants who were randomized did not start the study. Additionally, 3 withdrew during the first study week because of family ill health, job relocation, or time commitment required by the metabolic diet, and 2 were withdrawn because of either a transient elevation of liver enzymes or symptoms of muscle discomfort (FIGURE 1). Forty-six healthy, hyperlipidemic participants completed the study (25 men and 21 postmenopausal women); the mean (SE) age was 59 (1) years (range, 36-85 years) and mean (SE) body mass index (calculated as weight in kilo-

Figure 1. Flow of Patients Through the Trial



grams divided by the square of height in meters) was 27.6 (0.5) (range, 20.5-35.5) (TABLE 1). All participants had previously high LDL-C levels (>158 mg/dL [>4.1 mmol/L]).¹⁵ No participants had a history of cardiovascular disease, untreated hypertension (blood pressure $>140/90$ mm Hg), diabetes, or renal or liver disease, and none were taking medications known to influence serum lipids apart from 3 women who were taking stable doses of thyroxine, 1 of whom was also taking estrogen therapy. Twenty-one participants had started statins and had discontinued them at least 2 weeks prior to the study (9 control participants, 7 dietary portfolio participants, and 5 statin participants). Five participants were taking antihypertensive medications at a constant dose prior to and during the study. The majority ($n=26$) were taking vitamin preparations. Other, more commonly used non-prescription drugs and supplements taken throughout the study period included aspirin and anti-inflammatory drugs ($n=5$), calcium ($n=8$), glucosamine ($n=3$), grapeseed oil ($n=2$), saw palmetto ($n=2$), garlic ($n=2$), and magnesium ($n=2$).

Study Protocol

The study followed a randomized parallel design and was carried out between October and December 2002.

Participants followed their own low-saturated-fat therapeutic diets for 1 month prior to the start of the study. They were then stratified based on sex and pretreatment LDL-C level and were randomized to a very low-saturated-fat dairy and whole-grain cereal diet either with or without a statin or a diet containing viscous fibers, plant sterols, soy foods, and almonds. Each treatment lasted for 1 month. All foods were provided except for fresh fruits and vegetables. Body weight was measured weekly and blood samples were obtained after 12-hour overnight fasts at 2-week intervals. On each clinic visit, blood pressure was measured twice in the nondominant arm using a mercury sphygmomanometer by the same observer. Seven-day diet histories were obtained for the week prior to the 1-month treatment period. Completed menu checklists were returned at weekly intervals during the 4-week diet period and checked by the dietitians, who also recorded the participants' previous week's exercise and ensured that it was constant over the course of the study period.

At weekly intervals, participants recorded their overall feeling of satiety using a 9-point bipolar semantic scale in which -4 was excessively hungry, 0 was neutral, and $+4$ was discomfort due to excess food intake.

Table 1. Baseline Characteristics of Participants*

	Control		Statin		Dietary Portfolio	
	Men (n = 11)	Women (n = 5)	Men (n = 7)	Women (n = 7)	Men (n = 7)	Women (n = 9)
Race/ethnicity, No.						
European	8	5	7	6	6	9
East Indian	2	0	0	0	0	0
Chinese	1	0	0	0	0	0
Black	0	0	0	1	0	0
Hispanic	0	0	0	0	1	0
Age, y	60.4 (2.0)	60.4 (2.1)	54.4 (4.2)	59.6 (2.6)	51.6 (3.4)	65.1 (3.7)
Body weight, kg	82.9 (9.2)	65.1 (7.9)	84.9 (16.0)	74.4 (11.0)	84.2 (7.1)	66.6 (9.1)
Body mass index†	27.7 (0.8)	26.2 (0.9)	26.9 (1.7)	29.2 (1.4)	27.5 (0.6)	27.7 (1.2)
Blood pressure, mm Hg						
Systolic	119.0 (8.0)	123.0 (8.0)	126.0 (18.0)	122.0 (9.0)	121.0 (12.0)	125.0 (18.0)
Diastolic	76.0 (7.0)	75.0 (4.0)	82.0 (8.0)	80.0 (8.0)	80.0 (2.0)	74.0 (10.0)
Cholesterol, mmol/L‡						
Total	6.27 (0.79)	6.59 (1.14)	6.48 (0.68)	6.80 (0.75)	7.10 (1.27)	6.81 (0.69)
LDL-C	4.22 (0.69)	4.45 (1.08)	4.31 (0.76)	4.61 (0.72)	4.61 (1.04)	4.62 (0.86)
HDL-C	1.12 (0.21)	1.34 (0.34)	1.20 (0.17)	1.16 (0.18)	1.13 (0.16)	1.24 (0.45)
Triglycerides	2.05 (0.81)	1.76 (0.55)	2.15 (0.98)	2.28 (0.95)	2.99 (1.34)	2.06 (1.02)

*Data are expressed as mean (SD) unless otherwise noted. No significant baseline differences were observed when data for men and women were analyzed either separately or combined.

†Body mass index was calculated as weight in kilograms divided by the square of height in meters.

‡To convert total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) to mg/dL, divide by 0.0259; to convert triglycerides to mg/dL, divide by 0.0113.

Table 2. Nutritional Profiles of Self-selected Prestudy Diets Recorded by Participants Prior to Randomization*

	Control (n = 16)	Statin (n = 14)	Dietary Portfolio (n = 16)
Energy, kcal/d	1903	1766	1829
Total protein	84 (18.0)	79 (18.0)	80 (17.8)
Vegetable protein	38 (7.8)	38 (8.5)	35 (8.1)
Available carbohydrates	256 (53.9)	223 (50.3)	223 (49.4)
Total dietary fiber (g/1000 kcal)	30 (15.9)	28 (16.6)	28 (16.7)
Total fat	56 (26.1)	59 (30.3)	62 (30.3)
Saturated fatty acids	15 (7.0)	15 (7.6)	17 (8.1)
Monounsaturated fatty acids	24 (10.9)	27 (13.6)	27 (13.1)
Polyunsaturated fatty acids	12 (5.7)	13 (6.4)	13 (6.6)
Dietary cholesterol, mg/d (mg/1000 kcal)	190 (96.1)	142 (82.8)	161 (86.9)
Alcohol	6 (2.0)	3 (1.3)	8 (2.4)

*Data are expressed as mean grams per day (percentage of calories) unless otherwise noted.

Participants were randomized by the statistician using a random number generator and SAS version 6.12 software (SAS Institute Inc, Cary, NC) in a separate location from the clinic. The statistician held the code for the placebo and statin tablets provided with the control and statin diets, respectively. This aspect of the study was therefore double-blind. The dietitians were not blinded to the diet because they were responsible for patients' diets and for checking diet records. The laboratory staff re-

sponsible for analyses were blinded to treatment and received samples labeled with name codes and dates.

The study was approved by the ethics committees of the University of Toronto and St Michael's Hospital. Written informed consent was obtained from all participants.

Diets

The diets eaten before the 4-week study were the participants' routine therapeutic low-fat diets, which were similar to

current National Cholesterol Education Program guidelines (<7% energy from saturated fat and <200 mg/d of dietary cholesterol)¹⁵ and previously referred to as a Step II diet²¹ (TABLE 2).

During the 4-week study period, weight-maintaining diets were provided based on estimated caloric requirements using foods available in supermarkets and health food stores. All diets were vegetarian. The aim of the dietary portfolio was to provide 1.0 g of plant sterols per 1000 kcal of diet in a plant sterol ester-enriched margarine; 9.8 g of viscous fibers per 1000 kcal of diet from oats, barley, and psyllium; 21.4 g of soy protein per 1000 kcal as soy milk and soy meat analogs; and 14 g of whole almonds per 1000 kcal of diet. Emphasis was placed on eggplant and okra as additional sources of viscous fiber (0.2 g/1000 kcal and 0.4 g/1000 kcal, respectively). Thus, 200 g of eggplant and 100 g of okra were prescribed to be eaten as part of a 2000-kcal diet on alternate days. Eggs (1/wk) and butter (9 g/d) were also provided in the dietary portfolio to balance the saturated fat and dietary cholesterol in the control diet. This di-

etary portfolio has been described in detail previously.²²

The control diet used skim milk, fat-free cheese and yogurt, and egg substitute and liquid egg white to achieve low intake of saturated fat. High fiber intake was obtained by use of whole-grain breakfast cereals (fiber, 2.5 g/1000 kcal of diet) and bread (fiber, 2.0 g/1000 kcal of diet) made from 100% whole-wheat flour and wheat bran added to a high-dairy-protein muffin (fiber, 7.3 g/1000 kcal of diet). This diet therefore lacked sources of viscous fibers, plant sterols, and almonds. Skim-milk products replaced the soy and vegetable protein foods consumed as part of the dietary portfolio, and high monounsaturated sunflower oil (9 g/1000 kcal) and safflower oil (5 g/1000 kcal) were incorporated into the control diet (eg, muffins) to balance the fatty acid profile of the dietary portfolio. The macronutrient profile of the diets recorded as consumed in week 4 is shown in TABLE 3. Typical 1-day menus for the control diet and dietary portfolio are shown in TABLE 4.

Participants were provided with self-taring electronic scales (Salter Housewares, Kent, England) and asked to weigh all food items consumed prior to and during the study period. During the study period, all foods to be consumed by participants were provided initially by courier and then at weekly clinic visits, with the exception of fruit and low-calorie, non-starch-containing vegetables. Okra was the exception and was provided in the dietary portfolio. Participants were instructed to obtain specific fruits and vegetables from their local stores and were reimbursed on presentation of receipts. Participants were provided with a 7-day rotating menu plan on which they checked off each item as eaten and confirmed the weight of the foods. The same menu plan was used for all participants but was modified to suit individual preferences, provided that the goals for viscous fiber, soy protein, plant sterol, and almond consumption were met. Non-caloric beverages were not restricted.

Food use was made as straightforward as possible so that commercial

Table 3. Nutritional Profiles of Diets Provided and Recorded as Eaten at Week 4

	Control (n = 16)	Statin (n = 14)	Dietary Portfolio (n = 16)
Energy, kcal/d	2421	2519	2383
Total protein	134 (22.2)	131 (21.0)	128 (21.7)
Vegetable protein	26 (4.4)	28 (4.4)	127 (21.3)
Available carbohydrate	319 (52.8)	340 (53.8)	286 (48.0)
Total dietary fiber (g/1000 kcal)	57 (23.4)	57 (22.9)	78 (33.1)
Total fat	67 (24.6)	70 (24.9)	80 (30.0)
Saturated fatty acids	12 (4.5)	13 (4.6)	17 (6.3)
Monounsaturated fatty acids	28 (10.3)	28 (10.0)	34 (12.7)
Polyunsaturated fatty acids	23 (8.4)	26 (9.2)	27 (10.1)
Dietary cholesterol, mg/d (mg/1000 kcal)	28 (11.8)	31 (12.4)	54 (22.6)
Alcohol	0.3 (0.1)	0	0.4 (0.1)

*Data are expressed as mean grams per day (percentage of calories) unless otherwise noted.

dishes were ready for microwave or oven cooking, packs of instant soups were provided to be reconstituted with boiling water, and, when possible, meal portions were prescribed in multiples of whole units (eg, 1 cup of instant soup, 1 frozen dinner, 2 soy hot dogs, or 4 soy deli slices). Diet foods were packed in a designated central location and shipped by courier in separate boxes for dry, refrigerated, and frozen goods. Egg substitutes and soy and dairy foods were shipped in their commercial packages to be refrigerated on receipt by the participants.

Compliance was assessed from the completed weekly checklists and from the return of uneaten food items.

Statin Therapy

Twenty-milligram lovastatin tablets (Genpharm Inc, Etobicoke, Ontario) were crushed and delivered in Vegicap capsules (Capsugel, Morris Plains, NJ). Identical placebo capsules containing lactose and blue food coloring were also prepared (Pharmacy.ca, Toronto, Ontario). Both lovastatin and placebo capsules were dispensed by the hospital pharmacy in identical containers marked with the participant's name according to the randomization determined by the statistician. Participants were asked to take 1 capsule (20 mg of lovastatin or placebo) per day in the evening for the 28 days of the study and to return the containers for capsule counts at the end of the month.

Analyses

All samples from a given individual were labeled by code and analyzed in the same batch. Serum was analyzed according to the Lipid Research Clinics protocol²³ for total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) after dextran sulphate-magnesium chloride precipitation.²⁴ Low-density lipoprotein cholesterol was calculated.²⁵ Serum apolipoprotein A1 and B were measured by nephelometry (intra-assay coefficient of variation, 2.2% and 1.9%, respectively).²⁶ Serum samples, stored at -70°C , were analyzed for C-reactive protein by end-point nephelometry (coefficient of variation, 3.5%) (Behring BN-100, N high-sensitivity C-reactive protein reagent, Dade-Behring, Mississauga, Ontario).

Diets were analyzed using a program based on US Department of Agriculture data and developed in our laboratory to allow addition of data on foods relevant to ongoing studies after analysis in the laboratory for protein, total fat, and dietary fiber using American Organization of Analytical Chemists methods and fatty acids by gas chromatography.²² More than half of the foods used in the diets had been analyzed in the laboratory.

Statistical Analysis

Results were calculated as mean (SE). The mean differences in blood lipid values between week 2 and week 4 were not greater than 9.3 mg/dL (≤ 0.24 mmol/L)

(range, -7.7 to 9.3 mg/dL [-0.20 to 0.24 mmol/L]) and the week 4 level was therefore used throughout for all analyses as the end-point value. The significance of the differences between treatments was assessed by the Student-Neuman-Keuls multiple range test (SAS PROC GLM).²⁷ The analysis of covariance model used the change from week 0 to week 4 as the response variable and treatment and sex by treatment interaction as main effects, with baseline as covariate. Response variables were normally distributed, with the exception of C-reactive protein and the ratio of apolipoprotein B to apolipoprotein A1 in the dietary portfolio group, triglycerides in the statin

group, and body mass index in the control group. An intention-to-treat analysis was also carried out by including the 5 participants for whom baseline samples were available but who dropped out or were withdrawn prior to the week 2 blood sample. Three assumptions were assessed: that these participants would show no change, 50% of the mean change, or 100% of the mean change observed for that treatment. A 2-tailed paired *t* test was used to assess the significance of the percentage change from baseline. With 15 participants per treatment group, and assuming a 10% SD of effect with $\alpha = .05$ and $\beta = .80$, we had sufficient power to detect an 8% change in

LDL-C across treatments as significant. The CHD risk equations were used as described by Anderson et al.²⁸ Ten-year CHD risk was calculated, including in the model age, sex, systolic blood pressure, total cholesterol and HDL-C, smoking, diabetes, and definite electrocardiographic evidence of left ventricular hypertrophy.²⁸ Only 1 participant smoked and did so consistently throughout the study, and none had diabetes or evidence of left ventricular hypertrophy.

RESULTS

For the majority of participants, compliance was good as assessed from completed metabolic diet checklists and return of uneaten food items. When expressed as the percentage of prescribed calories recorded as eaten during week 4, compliance was 93% (3%) for control, 95% (3%) for statin, and 94% (3%) for the dietary portfolio. Similarly, 98% of capsules provided were taken. All participants believed they were eating as much food as they were capable of without experiencing discomfort (satiety rating, <3.0) at week 4 (control, 2.3 [0.4]; statin, 2.4 [0.3]; and dietary portfolio, 2.8 [0.2]). Participants lost a similar amount of weight in all 3 treatments (control, 0.3 [0.2] kg; $P = .22$; statin, 0.2 [0.1] kg; $P = .15$; dietary portfolio, 0.4 [0.2] kg; $P = .06$).

Blood Lipids and C-Reactive Protein

No differences were observed among the 3 treatment groups in baseline blood measurements. In the control group, percentage changes from baseline to week 4 were as follows: LDL-C, -8.0% (2.1%) ($P = .002$); LDL-C-HDL-C ratio, +3.0% (2.8%) ($P = .31$); and C-reactive protein, -10.0% (8.6%) ($P = .27$). In the statin and dietary portfolio groups, the respective data were as follows: LDL-C, -30.9% (3.6%) ($P < .001$) and -28.6% (3.2%) ($P < .001$); LDL-C-HDL-C ratio, -28.4% (4.2%) ($P < .001$) and -23.5% (3.2%) ($P < .001$); and C-reactive protein, -33.3% (8.3%) ($P = .002$) and -28.2% (10.8%) ($P = .02$), with no differences between week 2 and week 4 values (FIGURE 2). The reduc-

Table 4. Representative Diets Followed in Control/Statin and Dietary Portfolio Treatment Groups

Control/Statin	Dietary Portfolio
Breakfast	
Raisin bran cereal	Hot oat bran cereal
Skim milk	Soy beverage
Strawberries	Strawberries
Fat-free vanilla yogurt	Sugar and psyllium
Double-fruit jam	Oat bran bread
	Enriched margarine†
	Double-fruit jam
Snack*	
Bran muffin	Almonds
Light margarine	Soy beverage
Fresh fruit	Fresh fruit
Lunch	
Italian noodle soup with vegetables	Spicy black bean soup
Sandwich (grilled fat-free cheese, whole-wheat bread, light margarine)	Sandwich (soy deli slices, oat bran bread, enriched margarine†, lettuce, tomato, cucumber)
Salad (mixed greens and lettuce, tomato, cucumber, oil and vinegar dressing)	
Snack*	
Bran muffin	Almonds
Light margarine	Psyllium
Fresh fruit	Fresh fruit
Dinner	
Egg omelette (egg white, egg substitute, fat-free cheese, green peppers, onions, safflower oil)	Tofu bake with ratatouille (firm tofu, eggplant, onions, sweet peppers)
Pasta primavera	Pearled barley
Vegetables (eg, broccoli, cauliflower)	Vegetables (eg, broccoli, cauliflower)
Snack*	
Fresh fruit	Fresh fruit
Skim milk	Psyllium
	Soy beverage

*Snacks could be eaten with meals if desired.
†Margarine was enriched with plant sterols.

tions in blood lipids in both the dietary portfolio and statin groups were significantly greater ($P < .005$) than the respective changes in the control group for total cholesterol, LDL-C, apolipoprotein B, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, and apolipoprotein B to apolipoprotein A1, with no significant differences between the dietary portfolio and statin groups (TABLE 5). No differences in response were observed between sexes. In both the dietary portfolio and statin groups, C-reactive protein was reduced significantly more than in the control group ($P < .005$), but again, no difference was observed between the dietary portfolio and statin groups.

Blood Pressure

No significant treatment differences were observed in blood pressure (Table 5).

Calculated CHD Risk

In the dietary portfolio and statin groups, the calculated CHD risk was reduced similarly (24.9% [5.5%]; $P < .001$ and 25.8% [4.4%]; $P < .001$, respec-

tively). These reductions were also significantly different from the reduction (3.0% [5.2%]; $P = .57$) in the control group ($P < .005$) (Table 5). The risk reductions were largely due to the reductions in blood lipids. When blood pressure was held constant at 120 mm Hg in the risk equations, the blood lipid changes accounted for 70% and 82% of the risk reduction in the dietary portfolio and statin groups, respectively.

Intention-to-Treat Analysis


This study was also analyzed on the basis of intention to treat, including the 5 individuals with baseline values who dropped out or were withdrawn during the first and second weeks (before the week 2 and week 4 samples were taken for determination of blood lipids). (The 4 randomized participants for whom no baseline samples were obtained could not be included in this analysis.) Irrespective of whether it was assumed that the additional participants would have shown no response or 50% or 100% of the observed mean response, the same differences in blood

lipid levels were preserved as significantly different among the treatment groups, as observed when these participants were not included in the analysis. Furthermore, the mean reductions across treatments in LDL-C were still significant at -7.5% (2.0%) ($P = .002$) for control; -28.6% (3.2%) ($P < .001$) for dietary portfolio; and -24.0% (4.2%) ($P < .001$) for statin when it was assumed that the 5 additional participants showed no change in response to the treatments. Only for C-reactive protein and CHD risk was the significance level reduced (from $P < .005$ to $P < .05$) for the differences between control and both dietary portfolio and statin treatments.

COMMENT

These data confirm that use of a particular formulation of more recent general recommendations (ATP III, American Heart Association)^{15,16} can greatly enhance the cholesterol-lowering effect of diet. The reductions in blood lipids were not significantly smaller than those achieved with the initial dose of lovas-

Figure 2. Change From Baseline in LDL-C, LDL-C-HDL-C Ratio, and C-Reactive Protein



LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. Values are expressed as mean (SE) because, with the number of participants involved, approximately twice the SE represents a significant difference.

tatin, the first-generation statin marketed for cholesterol reduction.

The dietary components used in our portfolio are all well recognized for their cholesterol-lowering properties.^{1,16-20} Meta-analyses have indicated reductions in serum LDL-C of 6% to 7% for 9 to 10 g/d of psyllium,³ with smaller reductions for other viscous fibers²⁹; 13% for 1 to 2 g/d of plant sterols⁴; 12.5% for 45 g/d of soy protein²; and 1% for 10 g/d of almonds.¹ Lower intakes of saturated fat may lead to smaller reductions in cholesterol for soy protein,⁵ and the same may be true for other interventions, including plant sterols.³⁰ A reduction in LDL-C of 4% to 7% may therefore be more appropriate for each component when taken with very low-saturated-fat diets and account for the decrease in LDL-C of 28% observed in this dietary portfolio. In this study, the fatty acid and cholesterol intakes were both low and similar in the dietary portfolio and control groups. The benefits on blood lipids of higher monounsaturated fat intake associated with nut consumption, though not expected in the

present study because of the balanced fatty acid profiles of the diets,^{31,32} would be expected under conditions of mono-unsaturated fatty acid substitution.³¹⁻³⁴

The lower saturated fatty acid intakes made possible by the nature of the foods selected for the dietary portfolio may be a further advantage. Despite the relatively low saturated fatty acid and cholesterol content of the prestudy diets, application of the Hegsted equation³⁵ suggested that the differences in fatty acid and cholesterol intakes between the prestudy and study diets could account for 88%, 25%, and 27%, respectively, of the reductions observed in serum cholesterol in the control, statin, and dietary portfolio groups.

The different modes of action of the components on the dietary portfolio may have contributed to the additive effect. Viscous fibers increase bile acid losses,²⁹ plant sterols reduce cholesterol absorption,⁷ and soy proteins reduce hepatic cholesterol synthesis and increase LDL receptor messenger RNA and so potentially increase uptake of cholesterol.^{8,9} Almonds contain a mono-

unsaturated fatty acid- and plant sterol-rich oil that has been shown to lower LDL-C³⁴ together with vegetable proteins, fiber, and other phytochemicals, which are likely to operate through a range of mechanisms.¹⁰

Another feature of interest relating to the dietary portfolio was its ability to reduce C-reactive protein concentrations. This function, also observed with statins, has been related to their direct anti-inflammatory effect³⁶ and has been considered possibly responsible for some of the reduction in CHD observed with statin use, best demonstrated in women with normal LDL-C levels.³⁷ C-reactive protein reductions have not previously been reported with conventional cholesterol-lowering diets. It is therefore possible that lower C-reactive protein concentrations are a general consequence of effective cholesterol reduction, but in the present study, in common with other studies, C-reactive protein change was not significantly related to the change in LDL-C ($r=0.20$; $n=46$; $P=.17$).^{37,38} Also, in the present study, caution must be

Table 5. Effect of Control, Statin, and Dietary Portfolio Treatments on Blood Lipids, C-Reactive Protein, and Blood Pressure

	Control (n = 16)			Statin (n = 14)			Dietary Portfolio (n = 16)		
	Week 0	Week 4	Difference (SE)	Week 0	Week 4	Difference (SE)	Week 0	Week 4	Difference (SE)
Body weight, kg	77.4	77.1	-0.3 (0.2)	79.6	79.4	-0.2 (0.1)	74.3	74.0	-0.4 (0.2)
Cholesterol, mmol/L†									
Total	6.37	5.97	-0.40 (0.11)	6.64	5.09	-1.55 (0.23)*	6.94	5.41	-1.52 (0.22)*
LDL-C	4.29	3.93	-0.37 (0.09)	4.46	3.03	-1.43 (0.18)*	4.62	3.26	-1.36 (0.18)*
HDL-C	1.19	1.07	-0.12 (0.03)	1.18	1.14	-0.04 (0.04)	1.19	1.11	-0.08 (0.03)
Triglycerides	1.96	2.15	0.19 (0.15)	2.21	2.03	-0.19 (0.18)	2.47	2.28	-0.19 (0.18)
Apolipoproteins, g/L‡									
A1	1.54	1.44	-0.10 (0.03)	1.56	1.48	-0.08 (0.03)	1.57	1.45	-0.12 (0.03)
B	1.38	1.30	-0.08 (0.03)	1.43	1.05	-0.38 (0.05)*	1.49	1.15	-0.34 (0.06)*
Ratios									
Total cholesterol to HDL-C	5.53	5.78	0.25 (0.15)	5.75	4.51	-1.24 (0.22)*	6.14	5.09	-1.05 (0.24)*
LDL-C to HDL-C	3.73	3.78	0.05 (0.09)	3.85	2.68	-1.17 (0.17)*	4.10	3.07	-1.03 (0.19)*
Apolipoprotein B to A1	0.91	0.92	0.01 (0.02)	0.92	0.71	-0.21 (0.03)*	0.97	0.81	-0.17 (0.04)*
C-reactive protein, mg/L	1.36	1.08	-0.28 (0.16)	3.40	2.05	-1.50 (0.42)*	2.39	1.13	-1.25 (0.62)*
Blood pressure, mm Hg									
Systolic	120	113	-7.6 (2.7)	124	122	-2.4 (2.8)	123	117	-5.9 (2.9)
Diastolic	75	71	-4.1 (1.9)	81	76	-5.0 (1.8)	76	71	-5.4 (1.1)
10-Year coronary heart disease risk, %§	12.6	12.3	-0.3 (0.7)	11.3	7.9	-3.3 (0.9)*	11.0	8.1	-2.9 (0.5)*

*Comparisons of statin and dietary portfolio differences with control differences are statistically significant ($P<.005$) as assessed by Student-Neuman-Keuls procedure, but statin and dietary portfolio differences are not significantly different from each other.

†To convert total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) to mg/dL, divide by 0.0259; to convert triglycerides to mg/dL, divide by 0.0113.

‡To convert apolipoprotein A1 and B to mg/dL, multiply by 100.

§Coronary heart disease risk was estimated using the Framingham cardiovascular risk equation.²⁸

taken specifically in interpreting the C-reactive protein findings because of the substantial but nonsignificant differences between treatment baseline values and, more generally, because no intervention studies exist specifically to test the effect of C-reactive protein reduction on CHD risk.

The data currently available from clinical trials demonstrating reductions in cardiovascular disease risk support an important role for dietary change, which includes increased intakes of fiber, vegetable oils, and proteins from soy and other legumes, nuts, fruits, and vegetables.³⁹⁻⁴¹ Furthermore, in large cohort studies, high fiber intakes have consistently been associated with reduction in CHD risk³⁹ and CHD risk factors⁴²; more recently, so has increased nut consumption.⁴³⁻⁴⁵ In this respect, the recent dietary recommendations (ATP III, American Heart Association, US Food and Drug Administration) may further increase the effectiveness of diet in reducing the risk of cardiovascular disease. In the future, other plant food components with specific mechanisms of action may be added to this portfolio.⁴⁶⁻⁴⁸

Despite the effectiveness and safety of statins, there are still some individuals for whom physicians are reluctant to prescribe statins because of elevations of muscle or liver enzymes.⁴⁹ There are also those who would prefer to control their blood lipid levels by nonpharmacological means, particularly in view of recent, less satisfactory outcomes with statin use in older people.^{50,51} For such individuals, the dietary portfolio approach might provide a therapeutic option.

From our participants' perspective, of the 36 (78%) who completed the study and provided formal comments, 40% found the dietary portfolio acceptable with little further modification; however, an equal number thought that a greater variety of foods was required, 27% thought that the food volume was too great, and 13% required meat as part of their meals. The 5 most popular foods were almonds, ground soy (simulated ground beef), oat bran

cereal, oat bran bread, and plant sterol margarine.

In conclusion, current dietary recommendations¹⁵ focusing on diets low in saturated fat have been expanded to include foods high in viscous fibers (eg, oats and barley) and plant sterols. These guidelines, together with additional suggestions to include vegetable protein foods (soy)¹⁶ and nuts (almonds), appear to reduce LDL-C levels similarly to the initial therapeutic dose of a first-generation statin. However, before the true effectiveness of this dietary change can be assessed, studies must be undertaken in patients who assemble the diets for themselves on a routine basis. Using the experience gained, further development of this approach may provide a potentially valuable dietary option for cardiovascular disease risk reduction in primary prevention.

Author Affiliations: Clinical Nutrition and Risk Factor Modification Center (Drs Jenkins, Kendall, Faulkner, Josse, and Leiter, Mss Wong, Emam, and Parker, and Messrs Marchie, de Souza, and Vidgen) and Department of Medicine, Division of Endocrinology and Metabolism (Drs Jenkins, Josse, Leiter, and Connelly), St Michael's Hospital, and Departments of Nutritional Sciences (Drs Jenkins, Kendall, Faulkner, Josse, and Leiter, Mss Wong, Emam, and Parker, and Messrs Marchie, de Souza, and Vidgen), Medicine (Drs Jenkins, Josse, and Leiter), Biochemistry (Dr Connelly), and Laboratory Medicine and Pathobiology (Dr Connelly), Faculty of Medicine, University of Toronto, Toronto, Ontario; the Almond Board of California, Modesto (Dr Lapsley); and Unilever Health Institute, Unilever Research and Development, Vlaardingen, the Netherlands (Dr Trautwein).

Financial Disclosure: Dr Jenkins has received research grants from the Almond Board of California, Loblaws Brands Ltd, Yves Fine Foods (now Hain-Celestial Group), and Unilever Canada. Prior to undertaking research, he served on the scientific advisory board of Unilever Canada. He has received honoraria and financial support to attend scientific meetings from the Almond Board of California and Protein Technologies Inc (now Solae).

Author Contributions: *Study concept and design:* Jenkins, Kendall, Faulkner, Vidgen, Lapsley, Trautwein, Josse, Leiter.

Acquisition of data: Jenkins, Kendall, Marchie, Faulkner, Wong, de Souza, Emam, Parker, Vidgen, Connelly. *Analysis and interpretation of data:* Jenkins, Kendall, Faulkner, Parker, Vidgen, Trautwein, Leiter.

Drafting of the manuscript: Jenkins, Kendall, Trautwein. *Critical revision of the manuscript for important intellectual content:* Jenkins, Kendall, Faulkner, Marchie, Wong, de Souza, Emam, Parker, Vidgen, Lapsley, Trautwein, Josse, Leiter, Connelly. *Statistical expertise:* Vidgen.

Obtained funding: Jenkins, Kendall, Faulkner, Lapsley, Trautwein.

Administrative, technical, or material support: Kendall, Marchie, Faulkner, Wong, de Souza, Emam, Parker, Trautwein, Leiter, Connelly.

Study supervision: Jenkins, Kendall, Faulkner.

Funding/Support: This study was supported by the

Canada Research Chair Endowment of the federal government of Canada (CIHR CRC 950-01-31), the Canadian Natural Sciences and Engineering Research Council of Canada (CRD 247854-01), Loblaws Brands Ltd (Toronto, Ontario), the Almond Board of California, and Unilever Canada. Dr Jenkins holds a Canada Research Chair funded by the federal government of Canada.

Acknowledgment: We thank Loblaws Brands Ltd, the Almond Board of California, Unilever Research and Development, the Hain-Celestial Group (Melville, NY), Nestlé Canada Inc (Pickering, Ontario), Kraft Foods (Glenview, Ill), Procter & Gamble Inc (Toronto, Ontario), Bartlett Farms, Barwell Food Sales Inc (London, Ontario), and Burnbrae Farms Ltd (Upton, Quebec) for donation of foods used in this study. We thank Robert Chenaux and Larry C. Griffin of Loblaws Brands Ltd; Paul Schur, PhD, of Unilever Canada; Gerry Aman-tee, PhD, of the Hain-Celestial Group; Kathy Galbraith of Natural Temptations Bakery, Burlington, Ontario; Margaret C. Martini, PhD, of Kraft Foods; Don Bartlett of Bartlett Farms, Barwell Foods Sales Inc; the Stouffer's Marketing Team of Nestlé Canada; and Margaret Hudson of Burnbrae Farms Ltd, for their assistance on this project, and the study participants for their attention to detail and enthusiasm.

REFERENCES

- Jenkins DJ, Kendall CW, Marchie A, et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine and pulmonary nitric oxide: a randomized controlled crossover trial. *Circulation*. 2002;106:1327-1332.
- Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. *N Engl J Med*. 1995;333:276-282.
- Olson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. *J Nutr*. 1997;127:1973-1980.
- Law M. Plant sterol and stanol margarines and health. *BMJ*. 2000;320:861-864.
- Jenkins DJ, Kendall CW, Jackson CJ, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. *Am J Clin Nutr*. 2002;76:365-372.
- Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. *Eur J Clin Nutr*. In press.
- Lees AM, Mok HY, Lees RS, McCluskey MA, Grundy SM. Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. *Atherosclerosis*. 1977;28:325-338.
- Carroll KK. Review of clinical studies on cholesterol-lowering response to soy protein. *J Am Diet Assoc*. 1991;91:820-827.
- Baum JA, Teng H, Erdman JW Jr, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. *Am J Clin Nutr*. 1998;68:545-551.
- Kris-Etherton PM, Yu-Poth S, Sabate J, Ratcliffe HE, Zhao G, Etherton TC. Nuts and their bioactive individual constituents: effects on serum lipids and other factors that affect disease risk. *Am J Clin Nutr*. 1999;70(suppl):504S-511S.
- Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. *BMJ*. 1991;303:953-957.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 pa-

- tients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389.
13. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*. 1998;279:1615-1622.
 14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22.
 15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486-2497.
 16. Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines revision 2000: a statement for health-care professionals from the Nutrition Committee of the American Heart Association. *Circulation*. 2000;102:2284-2299.
 17. US Food and Drug Administration. *FDA Authorizes New Coronary Heart Disease Health Claim for Plant Sterol and Plant Stanol Esters*. Washington, DC: US Food and Drug Administration; 2000. Docket 001-1275, OOP-1276.
 18. US Food and Drug Administration. *Food Labeling: Health Claims: Soluble Fiber From Whole Oats and Risk of Coronary Heart Disease*. Washington, DC: US Food and Drug Administration; 2001:15343-15344. Docket 95P-0197.
 19. US Food and Drug Administration. *Food Labeling: Health Claims: Soluble Fiber From Certain Foods and Coronary Heart Disease*. Washington, DC: US Food and Drug Administration; 1998. Docket 96P-0338.
 20. US Food and Drug Administration. FDA final rule for food labeling: health claims: soy protein and coronary heart disease. 64 *Federal Register* 57699-57733 (1999).
 21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *JAMA*. 1993;269:3015-3023.
 22. Jenkins DJ, Kendall CW, Faulkner D, et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. *Metabolism*. 2002;51:1596-1604.
 23. Lipid Research Clinics. *Manual of Laboratory Operations: Lipid and Lipoprotein Analysis*. Washington, DC: US Government Printing Office; 1982. US Dept of Health and Human Services publication (NIH) 75-678.
 24. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg²⁺ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. *Clin Chem*. 1982;28:1379-1388.
 25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499-502.
 26. Fink PC, Romer M, Haeckel R, et al. Measurement of proteins with the Behring nephelometer: a multicentre evaluation. *J Clin Chem Clin Biochem*. 1989;27:261-276.
 27. *SAS/STAT User's Guide, Version 6.12*. Cary, NC: SAS Institute Inc; 1997.
 28. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. *Circulation*. 1991;83:356-362.
 29. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69:30-42.
 30. Mussner MJ, Parhofer KG, Von Bergmann K, Schwandt P, Broedl U, Otto C. Effects of phytosterol ester-enriched margarine on plasma lipoproteins in mild to moderate hypercholesterolemia are related to basal cholesterol and fat intake. *Metabolism*. 2002;51:189-194.
 31. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. *N Engl J Med*. 1986;314:745-748.
 32. Ginsberg HN, Barr SL, Gilbert A, et al. Reduction of plasma cholesterol levels in normal men on an American Heart Association Step 1 diet or a Step 1 diet with added monounsaturated fat. *N Engl J Med*. 1990;322:574-579.
 33. Kris-Etherton PM, Pearson TA, Wan Y, et al. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. *Am J Clin Nutr*. 1999;70:1009-1015.
 34. Hyson DA, Schneeman BO, Davis PA. Almonds and almond oil have similar effects on plasma lipids and LDL oxidation in healthy men and women. *J Nutr*. 2002;132:703-707.
 35. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. *Am J Clin Nutr*. 1965;17:281-295.
 36. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. *Arterioscler Thromb Vasc Biol*. 2001;21:115-121.
 37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*. 2002;347:1557-1565.
 38. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. *Circulation*. 2001;103:1933-1935.
 39. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). *Lancet*. 1992;339:563-569.
 40. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA*. 1998;280:2001-2007.
 41. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. *N Engl J Med*. 2000;343:16-22.
 42. Ludwig DS, Pereira MA, Kroenke CH, et al. Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. *JAMA*. 1999;282:1539-1546.
 43. Fraser GE, Sabate J, Beeson WL, Strahan TM. A possible protective effect of nut consumption on risk of coronary heart disease: the Adventist Health Study. *Arch Intern Med*. 1992;152:1416-1424.
 44. Hu FB, Stampfer MJ, Manson JE, et al. Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. *BMJ*. 1998;317:1341-1345.
 45. Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. *Arch Intern Med*. 2002;162:1382-1387.
 46. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr*. 1999;69:231-236.
 47. Adler AJ, Holub BJ. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men. *Am J Clin Nutr*. 1997;65:445-450.
 48. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. *J Nutr*. 2001;131(suppl):989S-993S.
 49. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lefant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *Circulation*. 2002;106:1024-1028.
 50. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA*. 2002;288:2998-3007.
 51. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360:1623-1630.